Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRN 00808

Drug Profile

CRN 00808

Alternative Names: CRN-00808

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Antisecretories; Small molecules
  • Mechanism of Action Somatostatin receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly

Most Recent Events

  • 13 Nov 2019 Crinetics plans a phase I trial for Acromegaly in Australia (PO, Capsule) (ACTRN12619001562167)
  • 23 Mar 2019 Final adverse events, efficacy and pharmacodynamic data from a phase I trial in healthy volunteers presented at the 101st Annual Meeting of the Endocrine Society (ENDO-2019)
  • 15 Jan 2019 Crinetics Pharmaceuticals initiates a phase II ACROBAT EDGE trial in Acromegaly (Treatment-experienced) in United Kingdom, Slovakia, Serbia, Germany and in USA (PO) (NCT03789656)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top